Drug Therapies Compared for Glucocorticoid-Induced Osteoporosis

The study included 795 subjects who were treated with either Prolia or oral risedronate
The study included 795 subjects who were treated with either Prolia or oral risedronate

Amgen announced top-line data from a primary analysis conducted in a Phase 3 study evaluating the safety and efficacy of Prolia (denosumab) vs. risedronate in patients receiving glucocorticoid treatment. 

The GIOP study (glucocorticoid-induced osteoporosis) was a 24-month, international, multicenter, randomized, double-blind, double-dummy, active-controlled trial (n=795) that met all primary and secondary endpoints at 12 months. The study evaluated Prolia 60mg subcutaneously (SC) every 6 months vs. oral risedronate 5mg daily. The primary endpoint was the percent change from baseline in lumbar spine bone mineral density (BMD) at 12 months assessing non-inferiority; secondary endpoints included the percent change from baseline in lumbar spine and total hip BMD assessing superiority. 

Related Articles

Compared to risedronate, patients treated with Prolia and receiving continuing glucocorticoid therapy for 12 months had significantly greater gains in BMD at the lumbar spine (4.4% vs. 2.3%) and total hip (2.1% vs. 0.6%), respectively. In patients newly initiating glucocorticoid therapy, treatment with Prolia resulted in greater BMD increases vs. risedronate, both at the lumbar spine (3.8% vs. 0.8%) and total hip (1.7% vs. 0.2%), respectively. Rates of adverse events and serious adverse events were similar across treatment arms and consistent with the known safety profile of Prolia. 

Prolia, a RANKL inhibitor, is approved for use in postmenopausal women with osteoporosis: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other therapy; to reduce incidence of vertebral, nonvertebral, and hip fractures; to increase bone mass in men with osteoporosis at high risk for fracture; to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer; to reduce incidence of vertebral fractures; and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Additional analysis of the results is ongoing and the study will remain double-blinded for an additional 12 months.

For more information call (800) 772-6436 or visit Prolia.com

Loading links....